Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease

Ali Moustapha, Arabi Naso, Maher Nahlawi, Anjan Gupta, Kristopher Arheart, Donald W. Jacobsen, Killian Robinson, Vincent W. Dennis

Research output: Contribution to journalArticle

399 Citations (Scopus)

Abstract

Background - Retrospective and case-control studies show that hyperhomocysteinemia is an independent risk factor for atherosclerosis in patients with end-stage renal disease. We studied prospectively the association between total homocysteine and cardiovascular outcomes. Methods and Results - In all, 167 patients (93 men, 74 women; mean age, 56.3±14.7 years) were followed for a mean duration of 17.4 ± 6.4 months. Cardiovascular events and causes of mortality were related to total homocysteine values and other cardiovascular risk factors. Cox regression analysis was used to identify the independent predictors for cardiovascular events and mortality. Fifty-five patients (33%) developed cardiovascular events and 31 (19%) died, 12 (8%) of cardiovascular causes. Total plasma homocysteine values ranged between 7.9 and 315.0 μmol/L. Levels were higher in patients who had cardiovascular events or died of cardiovascular causes (43.0±48.6 versus 26.9 ± 14.9 μmol/L, P=.02). The relative risk (RR) for cardiovascular events, including death, increased 1% per μmol/L increase in total homocysteine concentration (RR, 1.01; CI, 1.00 to 1.01; P=.01). Conclusions - These prospective observations confirm that hyperhomocysteinemia is an independent risk factor for cardiovascular morbidity and mortality in end-stage renal disease, with an increased R.R. of 1% per μmol/L increase in total homocysteine concentration. Interventional studies are needed to evaluate the possible effects of modifying this risk factor in these patients.

Original languageEnglish
Pages (from-to)138-141
Number of pages4
JournalCirculation
Volume97
Issue number2
StatePublished - Mar 31 1998
Externally publishedYes

Fingerprint

Hyperhomocysteinemia
Homocysteine
Chronic Kidney Failure
Prospective Studies
Mortality
Case-Control Studies
Atherosclerosis
Regression Analysis
Morbidity

Keywords

  • Artherosclerosis
  • Homocysteine
  • Kidney
  • Risk factors
  • Thrombosis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Moustapha, A., Naso, A., Nahlawi, M., Gupta, A., Arheart, K., Jacobsen, D. W., ... Dennis, V. W. (1998). Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation, 97(2), 138-141.

Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. / Moustapha, Ali; Naso, Arabi; Nahlawi, Maher; Gupta, Anjan; Arheart, Kristopher; Jacobsen, Donald W.; Robinson, Killian; Dennis, Vincent W.

In: Circulation, Vol. 97, No. 2, 31.03.1998, p. 138-141.

Research output: Contribution to journalArticle

Moustapha, A, Naso, A, Nahlawi, M, Gupta, A, Arheart, K, Jacobsen, DW, Robinson, K & Dennis, VW 1998, 'Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease', Circulation, vol. 97, no. 2, pp. 138-141.
Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart K, Jacobsen DW et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998 Mar 31;97(2):138-141.
Moustapha, Ali ; Naso, Arabi ; Nahlawi, Maher ; Gupta, Anjan ; Arheart, Kristopher ; Jacobsen, Donald W. ; Robinson, Killian ; Dennis, Vincent W. / Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. In: Circulation. 1998 ; Vol. 97, No. 2. pp. 138-141.
@article{173b5cdfb69948bea73eaa2d5a4cd730,
title = "Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease",
abstract = "Background - Retrospective and case-control studies show that hyperhomocysteinemia is an independent risk factor for atherosclerosis in patients with end-stage renal disease. We studied prospectively the association between total homocysteine and cardiovascular outcomes. Methods and Results - In all, 167 patients (93 men, 74 women; mean age, 56.3±14.7 years) were followed for a mean duration of 17.4 ± 6.4 months. Cardiovascular events and causes of mortality were related to total homocysteine values and other cardiovascular risk factors. Cox regression analysis was used to identify the independent predictors for cardiovascular events and mortality. Fifty-five patients (33{\%}) developed cardiovascular events and 31 (19{\%}) died, 12 (8{\%}) of cardiovascular causes. Total plasma homocysteine values ranged between 7.9 and 315.0 μmol/L. Levels were higher in patients who had cardiovascular events or died of cardiovascular causes (43.0±48.6 versus 26.9 ± 14.9 μmol/L, P=.02). The relative risk (RR) for cardiovascular events, including death, increased 1{\%} per μmol/L increase in total homocysteine concentration (RR, 1.01; CI, 1.00 to 1.01; P=.01). Conclusions - These prospective observations confirm that hyperhomocysteinemia is an independent risk factor for cardiovascular morbidity and mortality in end-stage renal disease, with an increased R.R. of 1{\%} per μmol/L increase in total homocysteine concentration. Interventional studies are needed to evaluate the possible effects of modifying this risk factor in these patients.",
keywords = "Artherosclerosis, Homocysteine, Kidney, Risk factors, Thrombosis",
author = "Ali Moustapha and Arabi Naso and Maher Nahlawi and Anjan Gupta and Kristopher Arheart and Jacobsen, {Donald W.} and Killian Robinson and Dennis, {Vincent W.}",
year = "1998",
month = "3",
day = "31",
language = "English",
volume = "97",
pages = "138--141",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease

AU - Moustapha, Ali

AU - Naso, Arabi

AU - Nahlawi, Maher

AU - Gupta, Anjan

AU - Arheart, Kristopher

AU - Jacobsen, Donald W.

AU - Robinson, Killian

AU - Dennis, Vincent W.

PY - 1998/3/31

Y1 - 1998/3/31

N2 - Background - Retrospective and case-control studies show that hyperhomocysteinemia is an independent risk factor for atherosclerosis in patients with end-stage renal disease. We studied prospectively the association between total homocysteine and cardiovascular outcomes. Methods and Results - In all, 167 patients (93 men, 74 women; mean age, 56.3±14.7 years) were followed for a mean duration of 17.4 ± 6.4 months. Cardiovascular events and causes of mortality were related to total homocysteine values and other cardiovascular risk factors. Cox regression analysis was used to identify the independent predictors for cardiovascular events and mortality. Fifty-five patients (33%) developed cardiovascular events and 31 (19%) died, 12 (8%) of cardiovascular causes. Total plasma homocysteine values ranged between 7.9 and 315.0 μmol/L. Levels were higher in patients who had cardiovascular events or died of cardiovascular causes (43.0±48.6 versus 26.9 ± 14.9 μmol/L, P=.02). The relative risk (RR) for cardiovascular events, including death, increased 1% per μmol/L increase in total homocysteine concentration (RR, 1.01; CI, 1.00 to 1.01; P=.01). Conclusions - These prospective observations confirm that hyperhomocysteinemia is an independent risk factor for cardiovascular morbidity and mortality in end-stage renal disease, with an increased R.R. of 1% per μmol/L increase in total homocysteine concentration. Interventional studies are needed to evaluate the possible effects of modifying this risk factor in these patients.

AB - Background - Retrospective and case-control studies show that hyperhomocysteinemia is an independent risk factor for atherosclerosis in patients with end-stage renal disease. We studied prospectively the association between total homocysteine and cardiovascular outcomes. Methods and Results - In all, 167 patients (93 men, 74 women; mean age, 56.3±14.7 years) were followed for a mean duration of 17.4 ± 6.4 months. Cardiovascular events and causes of mortality were related to total homocysteine values and other cardiovascular risk factors. Cox regression analysis was used to identify the independent predictors for cardiovascular events and mortality. Fifty-five patients (33%) developed cardiovascular events and 31 (19%) died, 12 (8%) of cardiovascular causes. Total plasma homocysteine values ranged between 7.9 and 315.0 μmol/L. Levels were higher in patients who had cardiovascular events or died of cardiovascular causes (43.0±48.6 versus 26.9 ± 14.9 μmol/L, P=.02). The relative risk (RR) for cardiovascular events, including death, increased 1% per μmol/L increase in total homocysteine concentration (RR, 1.01; CI, 1.00 to 1.01; P=.01). Conclusions - These prospective observations confirm that hyperhomocysteinemia is an independent risk factor for cardiovascular morbidity and mortality in end-stage renal disease, with an increased R.R. of 1% per μmol/L increase in total homocysteine concentration. Interventional studies are needed to evaluate the possible effects of modifying this risk factor in these patients.

KW - Artherosclerosis

KW - Homocysteine

KW - Kidney

KW - Risk factors

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0031914677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031914677&partnerID=8YFLogxK

M3 - Article

C2 - 9445164

AN - SCOPUS:0031914677

VL - 97

SP - 138

EP - 141

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 2

ER -